MARKET EOD
NIFTY 50:25,514.30▲ +1,075.32 (+4.40%)
SENSEX:83,021.75▲ +3,499.00 (+4.40%)
BANK NIFTY:63,063.00▲ +2,657.83 (+4.40%)
NIFTY IT:30,919.45▲ +1,303.12 (+4.40%)
MCX GOLD:₹129,814.00▼ -4,409.00 (-3.28%)
MCX SILVER:₹160,734.00▼ -8,968.00 (-5.28%)
MCX CRUDEOIL:₹7,647.00▼ -341.00 (-4.27%)
USD/INR:₹93.5136▼ -2.2589 (-2.36%)
YT X
Advertisement • SRK Money Talk
Home > Stock Market > Candel Therapeutics Discusses Clinical Delays and Upcoming Data at Jefferies Conference
Stock Market

Candel Therapeutics Discusses Clinical Delays and Upcoming Data at Jefferies Conference

By SRK Editorial Team • 2026-11-19 • ~2 min read
Candel Therapeutics Discusses Clinical Delays and Upcoming Data at Jefferies Conference
Advertisement • SRK Money Talk
Candel Therapeutics recently presented at the Jefferies Global Healthcare Conference, providing investors and analysts with updates regarding its clinical development pipeline, trial timelines, and upcoming data milestones. Introduction to Clinical Programs During the presentation, company leadership highlighted the ongoing clinical evaluation of their proprietary viral immunotherapy candidates. The discussion centered on how these novel agents are designed to stimulate an immune response against various solid tumors. Addressing Clinical Trial Timelines Executives addressed questions concerning recent timeline shifts within their development programs. They explained that ensuring comprehensive patient safety data collection and optimizing trial design required careful adjustments to the schedule. Anticipated Data Readouts Looking ahead, the organization outlined key milestones expected over the coming quarters. These upcoming data readouts are anticipated to offer deeper insights into the efficacy and safety profile of their lead candidates across different oncology indications. Strategic Outlook Management concluded by reiterating their commitment to advancing their clinical pipeline efficiently. They emphasized that maintaining rigorous scientific standards remains paramount as they progress toward future regulatory and clinical milestones.
Advertisement • SRK Money Talk
Share:XWAIN
RELATED STORIES